Teijin Pharma Limited, part of Japanese technology holding company Teijin Group (TSE:3401), and Merz Therapeutics GmbH, part of Germany's Merz Group, announced on Friday that Japan's Ministry of Health, Labour and Welfare has approved additional indications for XEOMIN (incobotulinumtoxinA) for the treatment of cervical dystonia and blepharospasm.

This expands XEOMIN's authorised uses in Japan to five indications, alongside existing approvals for the treatment of upper limb spasticity, lower limb spasticity and chronic sialorrhea.

The approval was supported by Phase III clinical trials conducted by Merz Therapeutics across Europe, North America and Asia, as well as Phase III studies conducted by Teijin in Japan. In the trials, XEOMIN demonstrated an ability to reduce involuntary muscle contractions by inhibiting the release of acetylcholine from cholinergic nerve endings.

As of April 2026, XEOMIN was approved in 79 countries for therapeutic and/or aesthetic indications and in 76 countries for the treatment of cervical dystonia and blepharospasm.

Teijin Limited entered into an exclusive licence and co-development agreement with Merz Therapeutics in 2017 and launched exclusive sales of XEOMIN in Japan in December 2020 following regulatory approval.